IDO2 and non-small cell lung carcinoma: Paclitaxel (PTX) is a first‐line chemotherapeutic drug for non‐small cell lung cancer (NSCLC) but it can induce indoleamine 2,3‐dioxygenase (IDO) activation, which severely lowers down its immuno‐chemotherapeutic effect.